Table 2.
The distribution of preserved antiglaucomatous medications used
| Medications | Patients, n (%) | Total (%) |
|---|---|---|
| Prostaglandines | ||
| Latanoprost (Xalatan®) | 30 (19.4) | 78 (50.3) |
| Travoprost (Travatan®) | 26 (16.8) | |
| Bimatoprost (Lumigan®) | 22 (14.2) | |
| Beta-blockers | ||
| Timolol (Tunolol®) | 4 (2.6) | 25 (16.1) |
| Carteolol (Carteol Lp®) | 20 (12.9) | |
| Bétaxolol (Betoptic®) | 1 (0.6) | |
| Carbonic anhydrase inhibitors | ||
| Dorzolamide (Alzor®) | 25 (16.1) | 29 (18.7) |
| Brinzolamide (Azopt®) | 4 (2.6) | |
| Alpha-2-Agonists=brimonidine (a2) (Alphagan®) | 16 (10.3) | 16 (10.3) |
| Pg + Bb* | ||
| Latanoprost + timolol (Xalacom®) | 16 (10.3) | 47 (30.3) |
| Travoprost + timolol (Duotrav®) | 24 (15.5) | |
| Bimatoprost + timolol (Ganfort®) | 7 (4.5) | |
| CAI + Bb† (dorzolamide + timolol) (Cosopt®, Zolol®) | 17 (10.9) | 17 (10.9) |
| a2 + Bb‡ (brimonidine + timolol) (Combigan®) | 2 (1.3) | 2 (1.3) |
*Fixed combination of Pg and Bb; †Fixed combination of carbonic anhydrase inhibitor and Bp; ‡Fixed combination of a2-adrenergic and Bb. a2: Alpha-2, Bp: Beta-blocker, Pg: Prostaglandin